No Data
No Data
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
ADRs Advance; Connect Biopharma Holdings Climbs 19%
Kangnai De Life Science (CNTB.US) is trapped on the eve of commercialization: the founder left and the stock price fell more than 30% in seven days.
On June 21st, the stock price of Kangnaide Biotechnology (CNTB.US) fell by 3.95%. This is the seventh trading day since its Chinese founding team completely left the company, and also the seventh trading day of the company's new round of stock price decline. During this period, the company's stock price has accumulated a 31.86% decline.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Connect Biopharma Hldgs Analyst Ratings
H.C. Wainwright Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $8